Publication Name	World Journal of Gastroenterology
Manuscript ID	25150
Country	United States

Received	2016-02-25 08:45
Peer-Review Started	2016-02-25 09:54
To Make the First Decision	2016-03-31 10:09
Return for Revision	2016-03-31 16:26
Revised	2016-04-08 06:40
Second Decision	2016-04-15 15:47
Accepted by Journal Editor-in-Chief	2016-04-17 17:51
Accepted by Executive Editor-in-Chief	2016-04-20 14:09
Articles in Press	2016-04-20 14:09
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-05-05 16:41
Publish the Manuscript Online	2016-05-19 14:49

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Current and emerging therapies in unresectable and recurrent gastric cancer
Manuscript Source	Invited Manuscript
All Author List	Erin Jou and Lakshmi Rajdev
Funding Agency and Grant Number
Corresponding Author	Lakshmi Rajdev, MD, Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, 1695 Eastchester Road, Bronx, NY 10467, United States. lrajdev@montefiore.org
Key Words	Advanced gastric cancer; Immunotherapy; Human epidermal growth factor receptor type 2; Targeted therapy; Vascular endothelial growth factor receptor
Core Tip	Despite many advances in medical and surgical treatments, gastric cancer remains the second leading cause of cancer deaths. There is a greater understanding of the molecular heterogeneity of gastric cancer in recent years, resulting in the development and clinical investigation of different targeted agents. This review will discuss current treatment strategies and highlight targeted therapies and emerging drugs for advanced gastric cancer.
Publish Date	2016-05-19 14:49
Citation	Jou E, Rajdev L. Current and emerging therapies in unresectable and recurrent gastric cancer. World J Gastroenterol 2016; 22(20): 4812-4823
URL	http://www.wjgnet.com/1007-9327/full/v22/i20/4812.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i20.4812

Full Article (PDF)	WJG-22-4812.pdf
Full Article (Word)	WJG-22-4812.doc
Manuscript File	25150-Review.docx
Answering Reviewers	25150-Answering reviewers.pdf
Audio Core Tip	25150-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	25150-Conflict-of-interest statement.pdf
Copyright License Agreement	25150-Copyright assignment.PDF
Peer-review Report	25150-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	25150-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	25150-Scientific misconduct check.pdf
Scientific Editor Work List	25150-Scientific editor work list.pdf